Target intelligence / Profile preview

Ocular surface glycocalyx

Molecular classification
Other (Carbohydrate-enriched cell surface layer), Glycocalyx, Membrane-associated mucins (includes MUC1, MUC4, MUC16, etc.), Proteoglycans, Glycolipids
01

Overview

The **ocular surface glycocalyx** is a complex carbohydrate-rich layer coating the epithelial cells of the cornea and conjunctiva. This structure is primarily composed of membrane-associated mucins (such as **MUC1, MUC4, MUC16, MUC20, MUC21, and MUC22**), proteoglycans, and glycolipids. The mucins form a dense, heavily glycosylated matrix that can reach hundreds of nanometers in thickness and extends from the apical cell surface into the tear film. The glycocalyx is essential for maintaining surface hydration, lubrication, wettability, and acts as both a physical and biochemical barrier, impeding pathogen adhesion and modulating inflammation. It associates with galectin-3 to form a protective galectin-glycan lattice. Breakdown of this structure is implicated in various ocular surface disorders such as **dry eye disease**, infections, allergies, and complications related to systemic diseases. Restoration or protection of the glycocalyx (e.g., via rebamipide) is a therapeutic goal in managing these conditions[1][2][3][4][5][6][7].

Other names
ocular surface mucinocular epithelial glycocalyxmembrane-associated mucin layerocular mucin glycocalyx
02

Mechanism of action

Upregulation/restoration of mucin expression, normalization of glycocalyx structure, enhanced barrier and lubrication

03

Biological functions

HydrationLubricationBarrier protectionAnti-adhesionRegulation of inflammationCell signalingMaintenance of epithelial wettability
04

Disease associations

Dry eye diseaseOcular surface infectionOcular allergyGraft-versus-host diseaseDiabetes-related ocular surface disease
05

Safety considerations

Disease-related: barrier breakdown leads to increased risk of infection, inflammation, and decreased lubricationtherapeutic challenges include restoration of glycocalyx integrity and chronic disease management
06

Interacting drugs

Rebamipide

1 more in the full profile.

07

Biomarkers

MUC16 expression in epithelial cellstear galectin-3 concentration

Beyond the preview

Go deeper on Ocular surface glycocalyx.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Ocular surface glycocalyx.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call